What is Protein G-MCC-DM1 ADC designed for?

Protein G-MCC-DM1 ADC is designed as an antibody-drug conjugate that uses a maleimidocaproyl (MCC) linker to attach DM1, a cytotoxic agent, to Protein G. It targets certain cancer cells through immunorecognition and delivers DM1 into cells to induce apoptosis by disrupting microtubule dynamics.

How does the MCC linker benefit the Protein G-MCC-DM1 ADC?

The MCC linker in the Protein G-MCC-DM1 ADC provides a stable connection between Protein G and DM1, ensuring that the cytotoxic payload remains attached until it is internalized by cancer cells. This stability helps in reducing off-target effects and enhancing the efficacy of the targeted therapy.

What is the role of Protein G in this ADC?

Protein G is utilized for its ability to bind to the Fc region of antibodies. This binding is crucial for the ADC as it allows the conjugate to be co-administered with monoclonal antibodies targeting specific cancer cells, enhancing the delivery of DM1 to its intended targets.

How does Protein G-MCC-DM1 ADC improve the pre-screening process of monoclonal antibodies?

The design of Protein G-MCC-DM1 ADC allows it to be utilized in the absence of a primary antibody, making it an efficient tool for evaluating the effectiveness of new monoclonal antibodies in targeting cancer cells. This can accelerate the development process by identifying promising antibody candidates earlier and more economically.

Are there any specific storage conditions for Protein G-MCC-DM1 ADC to maintain its stability and efficacy?

While specific storage conditions may vary, it is generally recommended to store ADCs at controlled temperatures to preserve their stability and functionality. Users should refer to the product documentation or contact Creative Biolabs directly for detailed storage instructions tailored to the Protein G-MCC-DM1 ADC to ensure optimal performance in experimental applications.

Home
Products
Anti-Ab ADCs
IgG Fc
Protein G-MCC-DM1 ADC

Protein G-MCC-DM1 ADC (CAT#: ADC-AA-050)

This ADC product is comprised of a Protein G conjugated via a MCC linker to DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, DM1 binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death. This product displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening monoclonal antibodies as ADC candidates.

ADC Target
ADC Antibody
ADC Linker
ADC payload drug

Name
IgG Fc

Overview
The fragment crystallizable region (Fc region) is composed of the constant region of the two heavy chains that form the IgG molecule. The Fc region of IgG bears a highly conserved N-glycosylation site. Glycosylation of the Fc fragment is essential for Fc receptor-mediated activity. Fc binds to various cell receptors and complement proteins thus mediating different physiological effects of antibodies, such as opsonization, antibody dependent cellular cytotoxicity (ADCC), degranulation of mast cells, basophils, eosinophils and other processes.

Overview
Protein G

Name
MCC (Maleimidomethyl cyclohexane-1-carboxylate)

Description
Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.

Name
DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)

Description
Derived from Maytansinoid,a group of cytotoxins structurally similar to rifamycin, geldanamycin, and ansatrienin. The eponymous natural cytotoxic agent maytansine is a 19-member lactam (ansa
macrolide) structure originally isolated from the Ethiopian shrub Maytenus ovatus. Maytansinoids can bind to tubulin at or near the vinblastine-binding site, which interfere the formation of microtubules and depolymerize already formed microtubules, inducing mitotic arrest in the intoxicated cells.

For Research Use Only. NOT FOR CLINICAL USE.

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

CAMouse™-Fully Human Antibody Generation Platform

Reviews

Literature

Protocol

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-AA-050. Click the button above to contact us or submit your feedback about this product.

Customer Reviews FAQ

Excellent

Impressive Performance

The Protein G-MCC-DM1 ADC from Creative Biolabs delivered exceptional results in our recent experiments. The well-designed mechanism involving the Fc region enhances its efficiency, making it indispensable for our research.

Excellent

Outstanding Results with Protein G-MCC-DM1 ADC! Our lab saw remarkable efficacy in targeting cancer cells, significantly reducing background issues. The absence of toxicity is a major plus, making this ADC an excellent choice for pre-screening antibodies.

Excellent

Protein G-MCC-DM1 ADC has been a game-changer in our cancer research. The specific targeting of DM1 via receptor-mediated endocytosis leads to precise cell death, with minimal off-target effects. Truly a top-notch product from Creative Biolabs.

Excellent

We've used various ADCs, but Protein G-MCC-DM1 stands out for its precise cancer cell targeting and effective induction of cell death. Plus, its safety profile without a primary antibody is unmatched.

Excellent

A Reliable Research Tool

The Protein G-MCC-DM1 ADC offers great specificity and negligible background noise in our trials. It's been crucial for our studies on microtubule dynamics in cancer cells.

Excellent

Highly Effective and Safe

The Protein G-MCC-DM1 ADC is revolutionary in its approach to cancer therapy, with no significant toxicity observed in our tests. Its role in antibody-dependent cellular cytotoxicity is particularly noteworthy.

Q: 1: What is Protein G-MCC-DM1 ADC designed for?
A: Protein G-MCC-DM1 ADC is designed as an antibody-drug conjugate that uses a maleimidocaproyl (MCC) linker to attach DM1, a cytotoxic agent, to Protein G. It targets certain cancer cells through immunorecognition and delivers DM1 into cells to induce apoptosis by disrupting microtubule dynamics.
Q: 2: How does the MCC linker benefit the Protein G-MCC-DM1 ADC?
A: The MCC linker in the Protein G-MCC-DM1 ADC provides a stable connection between Protein G and DM1, ensuring that the cytotoxic payload remains attached until it is internalized by cancer cells. This stability helps in reducing off-target effects and enhancing the efficacy of the targeted therapy.
Q: 3: What is the role of Protein G in this ADC?
A: Protein G is utilized for its ability to bind to the Fc region of antibodies. This binding is crucial for the ADC as it allows the conjugate to be co-administered with monoclonal antibodies targeting specific cancer cells, enhancing the delivery of DM1 to its intended targets.
Q: 4: How does Protein G-MCC-DM1 ADC improve the pre-screening process of monoclonal antibodies?
A: The design of Protein G-MCC-DM1 ADC allows it to be utilized in the absence of a primary antibody, making it an efficient tool for evaluating the effectiveness of new monoclonal antibodies in targeting cancer cells. This can accelerate the development process by identifying promising antibody candidates earlier and more economically.
Q: 5: Are there any specific storage conditions for Protein G-MCC-DM1 ADC to maintain its stability and efficacy?
A: While specific storage conditions may vary, it is generally recommended to store ADCs at controlled temperatures to preserve their stability and functionality. Users should refer to the product documentation or contact Creative Biolabs directly for detailed storage instructions tailored to the Protein G-MCC-DM1 ADC to ensure optimal performance in experimental applications.

Quick Links

ADC Toxins

Drug-linker Complexes

Customized ADCs

Anti-Ab ADCs

Other Products

Same Target Same Linker Same Payload

CAT#	Product Name	Linker	Payload
ADC-AA-054	Protein A-MCC-DM1 ADC	MCC (Maleimidomethyl cyclohexane-1-carboxylate)	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-AA-051	Protein G-Duocarmycin ADC		Duocarmycins
ADC-AA-031	anti-MIgG(Fc)Fab-N-DM1 ADC	Noncleavable linkers	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-AA-056	Anti-MIgG (clone 187.1)-VC-MMAE ADC	VC (valine-citrulline)	MMAE (Monomethyl auristatin E)
ADC-AA-027	anti-MIgG(Fc)Fab-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)

CAT#	Product Name	Linker	Payload
ADC-W-487	Anti-CD70-MCC-DM1 ADC	MCC (Maleimidomethyl cyclohexane-1-carboxylate)	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-W-622	Anti-CR2 (THB-5)-MCC-DM1 ADC	MCC (Maleimidomethyl cyclohexane-1-carboxylate)	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-W-512	Anti-ERBB2-SMCC-maytansine ADC	MCC (Maleimidomethyl cyclohexane-1-carboxylate)	maytansine
ADC-W-606	Anti-ERBB2-MCC-DM1 ADC	MCC (Maleimidomethyl cyclohexane-1-carboxylate)	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-W-578	Anti-CD74-MCC-Dox ADC	MCC (Maleimidomethyl cyclohexane-1-carboxylate)	doxorubicin

CAT#	Product Name	Linker	Payload
ADC-AA-031	anti-MIgG(Fc)Fab-N-DM1 ADC	Noncleavable linkers	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-AA-054	Protein A-MCC-DM1 ADC	MCC (Maleimidomethyl cyclohexane-1-carboxylate)	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-W-484	Anti-CD22 (clone hu10F4)-MCC-DM1 ADC	MCC (Maleimidomethyl cyclohexane-1-carboxylate)	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-W-496	Anti-EGFR-SMCC-DM1 ADC	SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate)	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-AA-026	anti-MIgG(Fc)-N-DM1 ADC	Noncleavable linkers	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)

Online Inquiry

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.